The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PMC: A more precise classifier of POLE mutations to identify candidates for immune therapy.
 
Fadl Zeineddine
No Relationships to Disclose
 
Benjamin Garmezy
No Relationships to Disclose
 
Timothy A. Yap
Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Axiom Biotechnologies; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; F-Star; Guidepoint Global; I-Mab; Ignyta; Janssen; Merck; Pfizer; Repare Therapeutics; Roche; Rubius Therapeutics; Schrodinger; Seagen; Varian Medical Systems; Zai Lab
Research Funding - Artios (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); ImmuneSensor Therapeutics (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tesaro (Inst); Vertex (Inst)
 
John Paul Y.C. Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax